Staurosporine

Catalog No.S1421 Synonyms: CGP 41251

Staurosporine Chemical Structure

Molecular Weight(MW): 466.53

Staurosporine is a potent PKC inhibitor for PKCα, PKCγ and PKCη with IC50 of 2 nM, 5 nM and 4 nM, less potent to PKCδ (20 nM), PKCε (73 nM) and little active to PKCζ (1086 nM) in cell-free assays. Also shows inhibitory activities on other kinases, such as PKA, PKG, S6K, CaMKII, etc. Phase 3.

Size Price Stock Quantity  
USD 270 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

3 Customer Reviews

  • Intracellular concentration of HSF1-phosphoserine 326, total HSF1, S6 kinase-phosphothreonine-389, total S6 kinase and β-actin, without or with heat shock in HeLa cells pretreated with mTOR inhibitors rapamycin (30 nM) and KU0063794 (2 uM) and kinase inhibitor staurosporine (100 nM) for 2 hr. Relative levels of HSF1-phosphoserine 326 in cells after the various treatments were determined by densitometric analysis of X-ray films, normalized to untreated cells (lane 1), and are indicated below the representation of the immunoblots.

    PLoS One 2012 7(6), e39679. Staurosporine purchased from Selleck.

    J Biomol Screen 2013 18(4), 388-99. Staurosporine purchased from Selleck.

  • J Biomol Screen 2013 18(4), 388-99. Staurosporine purchased from Selleck.

Purity & Quality Control

Choose Selective PKC Inhibitors

Biological Activity

Description Staurosporine is a potent PKC inhibitor for PKCα, PKCγ and PKCη with IC50 of 2 nM, 5 nM and 4 nM, less potent to PKCδ (20 nM), PKCε (73 nM) and little active to PKCζ (1086 nM) in cell-free assays. Also shows inhibitory activities on other kinases, such as PKA, PKG, S6K, CaMKII, etc. Phase 3.
Targets
PKCα [1]
(Cell-free assay)
c-Fgr [2]
(Cell-free assay)
phosphorylase kinase [2]
(Cell-free assay)
PKCη [1]
(Cell-free assay)
PKCγ [1]
(Cell-free assay)
2 nM 2 nM 3 nM 4 nM 5 nM
In vitro

Staurosporine, a microbial alkaloid, significantly inhibits protein kinase C from rat brain with IC50 of 2.7 nM. Staurosporine displays strong inhibitory effect against HeLa S3 cells with IC50 of 4 nM. [1] Staurosporine also inhibits a variety of other protein kinases, including PKA, PKG, phosphorylase kinase, S6 kinase, Myosin light chain kinase (MLCK), CAM PKII, cdc2, v-Src, Lyn, c-Fgr, and Syk with IC50 of 15 nM, 18 nM, 3 nM, 5 nM, 21 nM, 20 nM, 9 nM, 6 nM, 20 nM, 2 nM, and 16 nM, respectively. [2] Staurosporine (1 μM) induces >90% apoptosis in PC12 cells. Consistently, Staurosporine treatment induces a rapid and prolonged elevation of intracellular free calcium levels [Ca2+]i, accumulation of mitochondrial reactive oxygen species (ROS), and subsequent mitochondrial dysfunction. [3] The apoptosis of MCF7 cells induced by Staurosporine can be enhanced by the expression of functional caspase-3 via caspase-8 activation and Bid cleavage. [4] Staurosporine treatment at 1 μM only partially inhibits IL-3-stimulated Bcl2 phosphorylation but completely blocks PKC-mediated Bcl2 phosphorylation. [5] Staurosporine induces apoptosis of human foreskin fibroblasts AG-1518, depending on the lysosomal cathepsins D mediated cytochrome c release and caspase activation. [6] In addition to activating the classical mitochondrial apoptosis pathway, Staurosporine triggers a novel intrinsic apoptosis pathway, relying on the activation of caspase-9 in the absence of Apaf-1. [7]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human HeLa cells NInsWnFEgXSxdH;4bYPDqGG|c3H5 NYLTcpZSPDhiaB?= M3Pj[mN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhmVGFiY3XscJMh[W[2ZYKgOFghcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME20[U0xPiEQvF2u MYSyNVM5QDF7MR?=
human colon cancer cell line (LoVo cells) NVnJ[YFzWHKxbHnm[ZJifGmxbjDhd5NigQ>? MWfBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKGOxbH;uJINidmOncjDj[YxtKGyrbnWgLGxwXm9iY3XscJMqKHW|aX7nJG1VXCCjc4PhfUwhUUN3ME2wMlAxOSEQvF2u MYWxNVU6OTVyNR?=
human LoVo cells MUXQdo9tcW[ncnH0bY9vKGG|c3H5 MXm0PEB1dyB5MjDo Mmj1RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCOb2\vJINmdGy|IHHmeIVzKDR6IITvJFczKGi{czDifUBOXFRiYYPzZZk> NHuxZnEzOjF6MkmyPS=>
P19 cells NGf0c5RHfW6ldHnvckBie3OjeR?= M4HjZWlvcGmkaYTpc44hd2ZiUHzheIVt\XRvZHXybZZm\CCpcn;3eIgh\mGldH;yJJJm[2WydH;yJIlvKFBzOTDj[YxteyxiSVO1NF0xNjByMjFOwG0v NVnDcnZyOTV5N{G0NVk>
human BJ cells M17qWWN6fG:2b4jpZ:Kh[XO|YYm= NFzBUJc4OiCq NFHwN4FEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBDUiClZXzsd{Bi\nSncjC3NkBpenNiYomgR4Ft[2WrbjDBUUBie3OjeTygTWM2OD1yLkCwNkDPxE1w NIH1OFIzOjl{MUC4NS=>
human HT-29 cells M324bWZ2dmO2aX;uJIF{e2G7 M3XSOVIhcA>? M3TQTmVn\mWldDDvckBucXSxY3jvcoRzcWGuIH3lcYJz[W6nIIDveIVvfGmjbDDpckBpfW2jbjDIWE0zQSClZXzsd{Bi\nSncjCyJIhzeyC3c3nu[{BLSy1zIIP0ZYlvcW6pIHL5JIZtfW:{ZYPj[Y5k\SCjc4PhfS=> MlvSNlE1Ojh|N{W=
human A549 cells NIHIZXJEgXSxdH;4bYPDqGG|c3H5 M2fu[lczKGh? MoDTR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVU1QSClZXzsd{Bi\nSncjC3NkBpenNiYomgd5Vt\m:{aH;kZY1qdmViQjDt[ZRpd2R? NUS4e2dVOTh2OES3O|U>
human HT-29 cells Mmn6SpVv[3Srb36gZZN{[Xl? M1HMcWlvcGmkaYTpc44hd2ZibXn0c4Npd26mcnnhcEBu\W2kcnHu[UBxd3SnboTpZYwhcW5iaIXtZY4hUFRvMkmgZ4VtdHNidYPpcochUkNzIHT5[UB{fGGrbnnu[{BjgSCobIXvdoV{[2WwY3WgdIxifGVicnXh[IVzKGG|c3H5MEBKSzVyPUKuOUBvVQ>? NX;Qboh6OjF3MUOyPVM>
human HT-29 cells NGmxemdHfW6ldHnvckBie3OjeR?= M2K3V|IhcA>? M{S4TGlv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gbJVu[W5iSGStNlkh[2WubIOgZZN{\XO|ZXSgdoVlfWO2aX;uJI9nKG2rdH;jbI9v\HKrYXygcYVu[nKjbnWgdI91\W62aXHsJIFnfGW{IEKgbJJ{KGK7IIXzbY5oKEqFMTDzeIFqdmmwZzDifUBndHWxcnXzZ4Vv[2ViY3XscE1j[XOnZDDhd5NigSxiRVO1NF0zNjZibl2u MlHBNlE6PzNzMEG=
Sf9 cells MVrGeY5kfGmxbjDhd5NigQ>? MojiTY5pcWKrdHnvckBw\iCqdX3hckBUgWtiZYjwdoV{e2WmIHnuJHNnQSClZXzsd{whUUN3ME2zJI5ONg>? NHT0SYsyQDh{M{e4OC=>
human HUVEC MlvoVJJwdGmoZYLheIlwdiCjc4PhfS=> NGfVPWE1QCC2bzC3NkBp M1PPSmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSGXWSWMh[W[2ZYKgOFghfG9iN{KgbJJ{KGK7IF3UWEBie3OjeR?= M4\6c|IzOTh{OUK5
P19 cells NHXrZZJHfW6ldHnvckBie3OjeR?= M{K1cWlvcGmkaYTpc44hd2ZiUILveIVqdiCNaX7hd4UhSSCrbjDQNVkh[2WubIOsJGlEPTB;NDDuUU4> NVfIVHp6OTV5N{G0NVk>
Sf9 cells MmnLSpVv[3Srb36gZZN{[Xl? Ml3QTY5pcWKrdHnvckBw\iCqdX3hckBHgW5iZYjwdoV{e2WmIHnuJHNnQSClZXzsd{Bi\nSncjCxJI1qdiCkeTDFUGlUSSCrbjDwdoV{\W6lZTDv[kAyKHWvb3yvUEBCXFB? MkWzNVc{OTV6NUO=
Sf21 cells NWjLT4tCTnWwY4Tpc44h[XO|YYm= M4rzdGlvcGmkaYTpc44hd2ZiSlHLN{BmgHC{ZYPz[YQhcW5iU3[yNUBk\WyuczygTWM2OD14IH7NMi=> MlH4NVcxQDhyNUm=
human colon carcinoma cell line HCT116 MWnGeY5kfGmxbjDhd5NigQ>? M1S0PGNwdmOnboTyZZRqd25icnXxeYlz\WRiZn;yJIdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJINwdG:wIHPhdoNqdm:vYTDj[YxtKGyrbnWgTGNVOTF4LDDJR|UxRTZibl2u MmqzNVU2Ozd|NEW=
human ST486 cells NGPyV|NRem:uaX\ldoF1cW:wIHHzd4F6 MVq0PEB1dyB5MjDo MnrQRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCVVES4OkBk\WyuczDh[pRmeiB2ODD0c{A4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVchdk1w MlTDNlIyQDJ7Mkm=
human MDA-MB-231 cells M{L1XmN6fG:2b4jpZ:Kh[XO|YYm= MVW3NkBp M4PzbWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1FSS2PQj2yN|Eh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IIP1cIZwemixZHHtbY5mKEJibXX0bI9lNCCJSUWwQVcvOSCwTT6= M3S3cFE5PDh2N{e1
P19 cells M4rkW2Z2dmO2aX;uJIF{e2G7 MkfDTY5pcWKrdHnvckBw\iCFeXPsbY4u\GWyZX7k[Y51KGurbnHz[UAyKGmwIGCxPUBk\WyuczygTWM2OD16IH7NMi=> MYOxOVc4OTRzOR?=
human DLD1 cells M1\DXXBzd2yrZnXyZZRqd25iYYPzZZk> M{D3W|Q5NTd{IHi= MU\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKESOREGgZ4VtdHNiYX\0[ZIhPDhidH:gO|IhcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME25JI5ONg>? MXWyNlE5Ojl{OR?=
insect cells NFTmb2dHfW6ldHnvckBie3OjeR?= NWjkW4tJUW6qaXLpeIlwdiCxZjDoeY1idiC{ZXPvcYJqdmGwdDDQbY0yKGW6cILld5Nm\CCrbjDpcpNm[3RiY3XscJMh[nliSGTSSkwhUUN3ME2xNEBvVS5? MVGxPVE4QTB5Nh?=
V79 MZ cells MUTGeY5kfGmxbjDhd5NigQ>? NWHZSHk{UW6qaXLpeIlwdiCxZjDoeY1idiCjbHTvd5Rmem:wZTDzfY51cGG|ZTDlfJBz\XO|ZXSgbY4hXjd7IF3aJINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiYXzkc5N1\XKxbnWgd5lvfGinc3nzMEBKSzVyPUGxJI5ONg>? MYKyOFQzOjVzOR?=
P19 cells M1;JV2Z2dmO2aX;uJIF{e2G7 MXzJcohq[mm2aX;uJI9nKF[jc3P1cIFzKGWwZH;0bIVtcWGuIHfyc5d1cCCoYXP0c5IhemWlZYD0c5IhcW5iUEG5JINmdGy|LDDJR|UxRTF2IH7NMi=> NFPqUlMyPTd5MUSxPS=>
Sf9 cells NFrUVnZHfW6ldHnvckBie3OjeR?= M4O5TFIxKG2rboO= MnPXTY5pcWKrdHnvckBw\iCqdX3hckBHgW5iZYjwdoV{e2WmIHnuJHNnQSClZXzsd{Bi\nSncjCyNEBucW6|IHL5JGVNUVODIHnuJJBz\XOnbnPlJI9nKDFidX3vcE9NKEGWUDygTWM2OD1zNTDuUU4> Mnj3NVc{OTV6NUO=
human PBMC NF\mcJlHfW6ldHnvckBie3OjeR?= M4HwXVI1KGh? MojBV5VxeHKnc4Ppc44hd2ZiSVyyJJBzd2S3Y4Tpc44hcW5iaIXtZY4hWEKPQzDh[pRmeiB{NDDodpMh[nliRVzJV2EtKEmFNUC9NVYhdk1w Mn\zNVg2QDVyNE[=
human A549 cells NVHa[I1lS3m2b4TvfIlkyqCjc4PhfS=> NHvu[JY1QCCq NXj0OIxMS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTV2OTDj[YxteyCjZoTldkA1QCCqcoOgZpkhVVSWIHHzd4F6KCxiSVO1NF0zOCCwTT6= NF7jU2YzPTh{NUmzOC=>
human CEM cells M3;R[WN6fG:2b4jpZ:Kh[XO|YYm= NISxdZg4OiCq NILlTHZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBETU1iY3XscJMh[W[2ZYKgO|IhcHK|IHL5JGNidGOnaX6gRW0h[XO|YYmsJGlEPTB;MkOgcm0v NIHmVHozOjl{MUC4NS=>
human HeLa cells NXmwVoNYS3m2b4TvfIlkyqCjc4PhfS=> MknNOFghcA>? MnnuR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTIVN[SClZXzsd{Bi\nSncjC0PEBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUK1JI5ONg>? MXiyOVgzPTl|NB?=
human PC3 cells NUG2UpYxS3m2b4TvfIlkyqCjc4PhfS=> MUm0PEBp NHvpW4dEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBRSzNiY3XscJMh[W[2ZYKgOFghcHK|IHL5JG1VXCCjc4PhfUAtKEmFNUC9N|Ehdk1w MXeyOVgzPTl|NB?=
human SF268 cells NFftXZVEgXSxdH;4bYPDqGG|c3H5 MVG0PEBp NVHybJVbS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hW0Z{NkigZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KFOUQjDhd5NigSxiR1m1NF01PCCwTT6= M{T1fVIyPTF|Mkm0
human MCF7 cells NHfnbFlEgXSxdH;4bYPDqGG|c3H5 MVO0PEBp MnXTR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWNHPyClZXzsd{Bi\nSncjC0PEBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUWwJI5ONg>? MkDjNlE{QDhzOUG=
HEK293 cells NULwWXQ5S3m2b4TvfIlkyqCjc4PhfS=> NIfMVpg4OiCq NHHEfItEgXSxdH;4bYNqfHliYXfhbY5{fCCKRVuyPVMh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IFPlcIxVcXSnclfsc{Bie3OjeTygTWM2OD13NjDuUU4> MUOyOFc3OzJ4Mh?=
HUE cells MYTGeY5kfGmxbjDhd5NigQ>? M4[zT|kxKG2rboO= NYTQfXF{UW6qaXLpeIlwdiCxZjDWSWdHWjJiaX6gTHVGKGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gWmVITi2rbnT1Z4VlKGG3dH;wbI9{eGixconsZZRqd25idILlZZRm\CCob4KgPVAhdWmwczDi[YZwemViVlXHSkBkcGGubHXu[4Uh[nliRVzJV2EtKEmFNUC9O|Ahdk1w NELTOHEzODF5MEG2Ny=>
human A431 cells NXjBeJJUS3m2b4TvfIlkyqCjc4PhfS=> MmfrNlQhKGh? M{DQZWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGE1OzFiY3XscJMh[W[2ZYKgNlQhcHK|IIXzbY5oKEGwbnX4bY4hXmWISWTDM5Bzd3CrZHn1cUBqd2SrZHWgd5RicW6rbnegZpkhVVSWIHHzd4F6NCCLQ{WwQVcxKG6PLh?= Ml3pNlI2PDFyNUG=
human Jurkat cells NV\jNJdRWHKxbHnm[ZJifGmxbjDhd5NigQ>? M3HId2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgTmFMOyCneIDy[ZN{cW6pIFnMNk1{fGmvdXzheIVlKGi3bXHuJGp2emujdDDj[YxteyxiSVO1NF04OSCwTT6= NHHKPXIyQTR{N{KwNy=>
HEK293 cells NFTk[FNHfW6ldHnvckBie3OjeR?= MmTRTY5pcWKrdHnvckBw\iCLTD24JJJmdGWjc3WgZpkhUEWNMkmzJINmdGy|IHX4dJJme3OrbnegVGtENWKndHGyMEBKSzVyPUe3JI5ONg>? NWn2PHhmOTV5N{G0NVk>
human KE-97 cells NGrpSGpEgXSxdH;4bYPDqGG|c3H5 NXGwSnJMPzJiaB?= NXmzfGNLS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hU0VvOUegZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KEOnbHzUbZRz\S2JbH:gcJVucW6nc3PlcpQh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5zMzFOwG0v M4fo[FI1OzJ6Mkiz
human CHOK1 cells NELKR2REgXSxdH;4bYPDqGG|c3H5 MnTsOFghcA>? NVrHe3hOS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hS0iRS{GgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KFOUQjDhd5Nige,:jDDJR|UxRTBwMUOg{txONg>? NXHVZ29MOjF3MUOyPVQ>
mouse NIH/3T3 cells Mmf4R5l1d3SxeHnjxsBie3OjeR?= NE\ueXA6PiCq NH\NZ4NEgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBPUUhxM2SzJINmdGy|IHHmeIVzKDl4IHjyd{BjgSCVUlKgZZN{[XluIFnDOVA:OC5{IN88UU4> Mm[5NlQ{PjF3MkG=
human A2780 cells M2nwNmN6fG:2b4jpZ:Kh[XO|YYm= M3P0SFk3KGh? M17NN2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGEzPzhyIHPlcIx{KGGodHXyJFk3KGi{czDifUBUWkJiYYPzZZktKEmFNUC9NE4zKM7:TT6= MYqyOFM3OTV{MR?=
human 8505C cells M33MOGN6fG:2b4jpZ:Kh[XO|YYm= NXy2[YNMQTZiaB?= Mkm0R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gPFUxPUNiY3XscJMh[W[2ZYKgPVYhcHK|IHL5JHNTSiCjc4PhfUwhUUN3ME2wMlIh|ryPLh?= M3;BPFI1OzZzNUKx
human 518A2 cells MkXFR5l1d3SxeHnjxsBie3OjeR?= MYe5OkBp NGrQO4tEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckA2OTiDMjDj[YxteyCjZoTldkA6PiCqcoOgZpkhW1KEIHHzd4F697zOIFnDOVA:OC5{IN88UU4> NIP3Z|UzPDN4MUWyNS=>
human HuH7 cells MWTDfZRwfG:6aXRCpIF{e2G7 MlPnO|IhcA>? MXXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIeWg4KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDD[YxtXGm2cnWtS4xwKGy3bXnu[ZNk\W62IHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNlMh|ryPLh?= NWTVTG55OjR|MkiyPFM>
FL5.12-Akt1 cells MWjQdo9tcW[ncnH0bY9vKGG|c3H5 NGDqe|FCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JGZNPS5zMj3Bb5QyKGOnbHzzJIJ6KE2WVDDhd5NigSxiSVO1NF0xNjJ7IN88UU4> MWmxOlQxOzZ{Nh?=
human MiaPaCa-2 cells MYrQdo9tcW[ncnH0bY9vKGG|c3H5 MYrBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2rYWDhR4EuOiClZXzsd{whUUN3ME2wMlM4KM7:TT6= NF7ybJUyPjRzM{e4NC=>
human BGC823 cells NHntbXpEgXSxdH;4bYPDqGG|c3H5 MmezO|IhcA>? MWjDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDCS2M5OjNiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JGNmdGyWaYTy[U1IdG9ibIXtbY5me2OnboSgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4{QCEQvF2u NVTWZpZXOjR|MkiyPFM>
human MCF7 cells M2nYS2N6fG:2b4jpZ:Kh[XO|YYm= MoToPVYhcA>? Mon6R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWNHPyClZXzsd{Bi\nSncjC5OkBpenNiYomgV3JDKGG|c3H5MEBKSzVyPUCuOEDPxE1w MXyyOFM3OTV{MR?=
human A549 cells MkX5R5l1d3SxeHnjxsBie3OjeR?= MWe5OkBp Mkf2R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVU1QSClZXzsd{Bi\nSncjC5OkBpenNiYomgV3JDKGG|c3H5MEBKSzVyPUCuOkDPxE1w M172bFI1OzZzNUKx
HEK293 cells M4O0WGN6fG:2b4jpZ:Kh[XO|YYm= NYjXe21yS3m2b4TvfIlkcXS7IHHnZYlve3RiSFXLNlk{KGOnbHzzMEBGSzVyPUKg{txONg>? NHv6UG4zPTNzNkOxOy=>
human Raji cells  M4jLNGN6fG:2b4jpZ:Kh[XO|YYm= Ml;2R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gVoFrcSClZXzsd{whTUN3ME2yJO69VS5? MlT5NlU{OTZ|MUe=
human HepG2 cells NFzJepVEgXSxdH;4bYPDqGG|c3H5 Mm\4R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTIVxTzJiY3XscJMtKEWFNUC9NkDPxE1w MVuyOVMyPjNzNx?=
human BJ cells NXrYPXpXS3m2b4TvfIlkyqCjc4PhfS=> MYrDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDCTkBk\WyuczygSWM2OD1{IN88UU4> M1;YN|I2OzF4M{G3
human U937 cells NFXlTZlEgXSxdH;4bYPDqGG|c3H5 M{[yOmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHU6OzdiY3XscJMtKEmFNUC9NkDPxE1w NFfXWocyPzB6OEC2Oy=>

... Click to View More Cell Line Experimental Data

In vivo In the gerbil and rat ischemia models, Staurosporine pretreatment (0.1-10 ng) before ischemia prevents neuronal damage in a dose-dependent manner, suggesting the involvement of PKC in CAl pyramidal cell death after ischemia. [8]

Protocol

Kinase Assay:

[1]

+ Expand

Enzyme assay and binding assay:

Protein kinase C is assayed in a reaction mixture (0.25 mL) containing 5 μmol of Tris/HCl, pH 7.5, 2.5 μmol of magnesium acetate, 50 μg of histone II S, 20 μg of phosphatidylserine, 0.88 μg of diolein, 125 nmol of CaCl2, 1.25 nmol of [γ-32]ATP (5-10 × 104 cpm/nmol) and 5 μg of partially purified enzyme. The binding of [3H]PDBu to protein kinase C is determined: Reaction mixture (200 μL contained 4 μmo1 of Tris/malate, pH 6.8, 20 μmol of KCl, 30 nmol of CaC12, 20 μg of phosphatidylserine, 5 μg of partially purified protein kinase C, 0.5% (final concentration) of DMSO,10 pmol of [3H]PDBu (l-3 × 104 cpm/pmol) and 10 μL of various amounts of Staurosporine.
Cell Research:

[3]

+ Expand
  • Cell lines: PC12
  • Concentrations: Dissolved in DMSO, final concentration 1 μM
  • Incubation Time: ~32 hours
  • Method:

    Cells are exposed to Staurosporine for ~32 hours. Cells are fixed in 4% paraformaldehyde and stained with the DNA-binding dye Hoechst 33342. Cells are visualized under epifluorescence illumination, and the percentage of apoptotic cells (cells with condensed and fragmented DNA) is determined.


    (Only for Reference)
Animal Research:

[8]

+ Expand
  • Animal Models: Male Mongolian gerbils or male Wistar rats subjected to transient ischemia
  • Formulation: Dissolved in DMSO, and diluted in saline
  • Dosages: ~10 ng
  • Administration: Stereotaxically administered into the bilateral CAl subfield of the hippocampus
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 4 mg/mL (8.57 mM)
Water Insoluble
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 466.53
Formula

C28H26N4O3

CAS No. 62996-74-1
Storage powder
Synonyms CGP 41251

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00301938 Completed Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Acute Promyelocytic Leukemia (M3)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Blastic Phase Chronic Myelogenous Leukemia|Myelodysplastic/Myeloproliferative Neoplasms|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Relapsing Chronic Myelogenous Leukemia|Secondary Acute Myeloid Leukemia|T-cell Adult Acute Lymphoblastic Leukemia|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Adult Acute Myeloid Leukemia National Cancer Institute (NCI) December 2005 Phase 1
NCT00098956 Completed Extensive Stage Small Cell Lung Cancer|Recurrent Small Cell Lung Cancer National Cancer Institute (NCI) January 2005 Phase 2
NCT00082017 Completed Lymphoma, Large-Cell, Ki-1|Lymphoma, T-Cell National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) April 2004 Phase 2
NCT00072267 Completed Fallopian Tube Cancer|Ovarian Cancer|Primary Peritoneal Cavity Cancer University Health Network, Toronto|National Cancer Institute (NCI) January 2004 Phase 2
NCT00072189 Terminated Recurrent Melanoma|Stage IV Melanoma National Cancer Institute (NCI) November 2003 Phase 2
NCT00030888 Unknown status Kidney Cancer University of California, San Francisco|National Cancer Institute (NCI) December 2002 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PKC Signaling Pathway Map

Related PKC Products

Tags: buy Staurosporine | Staurosporine supplier | purchase Staurosporine | Staurosporine cost | Staurosporine manufacturer | order Staurosporine | Staurosporine distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID